CAS No. |
156251-01-3 |
|---|---|
中文名称 |
(2S,5S,8S,11S,17S,23S,26S,29S)-29-氨基-11,17-二((S)-仲丁基)-5-((R)-1-羟基乙基)-8-异丁基-2-异丙基-23,26-二甲基-4,7,10,13,16,19,22,25,28-九氧代-3,6,9,12,15,18,21,24,27-九氮杂三十烷二酸 |
英文名称 |
(2S,5S,8S,11S,17S,23S,26S,29S)-29-amino-11,17-di((S)-sec-butyl)-5-((R)-1-hydroxyethyl)-8-isobutyl-2-isopropyl-23,26-dimethyl-4,7,10,13,16,19,22,25,28-nonaoxo-3,6,9,12,15,18,21,24,27-nonaazadotriacontanedioic acid |
别名 |
H-GLU-ALA-ALA-GLY-ILE-GLY-ILE-LEU-THR-VAL-OH;GLU-ALA-ALA-GLY-ILE-GLY-ILE-LEU-THR-VAL;EAAGIGILTV;ANTIGEN SK29-AA (26-35) (HUMAN);ANTIGEN LB39-AA (26-35) (HUMAN);MART-1 (26-35) (HUMAN);MELANOMA ANTIGEN RECOGNIZED BY T-CELLS 1 (26-35) (HUMAN);MELAN-A PROTEIN (26-35) (HUMAN) |
标准英文名 |
(2S,5S,8S,11S,17S,23S,26S,29S)-29-amino-11,17-di((S)-sec-butyl)-5-((R)-1-hydroxyethyl)-8-isobutyl-2-isopropyl-23,26-dimethyl-4,7,10,13,16,19,22,25,28-nonaoxo-3,6,9,12,15,18,21,24,27-nonaazadotriacontanedioic acid |
MDL No. |
MFCD06657941 |
分子式 |
C42H74N10O14 |
分子量 |
943.11 |
精确分子量 |
942.54 |
SMILES |
CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C(C)C)[C@@H](C)O)[C@@H](C)CC |
标准SMILES |
C[C@@H](O)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O |
用途 |
Used in cancer immunotherapy as a clinical vaccine; serves as a T-cell epitope (residues 26–35 of MART-1/Melan-A protein) for immune recognition of melanoma cells; utilized to study T-cell recognition of multiple peptides and to design peptide variants that elicit altered immunological responses. |
InChIKey |
TUIOKRGNEZUFAI-NMIMMQBESA-N |
|
|
评论 |
|---|